The Czech Republic's Chamber of Pharmacists has announced that its members will refuse to collect patient charges for prescription drugs as outlined by the country's Health Ministry. The Ministry has introduced higher patient charges for prescription drugs than originally indicated in a new draft of the government's health reform legislation. The new proposals add in charges for visits to general practitioners and also increase those for prescribed drugs to 1.07 euros ($1.45) per prescription.
Tomas Julinek, the Health Minister, is due to propose the legislation in the near future with the intention that it will take effect in January next year. The charges are collected on behalf of all patients over three years old. However, the pharmacists' leader, Lubomir Chudoba, said the Ministry has been warned that pharmacists will not collect the increased charges. He said these would have to be collected by doctors in order to make certain that patients received their prescribed drugs.
Mr Chuboda claimed that many patients do not collect their medicines from pharmacies at present, because they cannot afford the charges. The pharmacy organization has also said that, while part of the patient charge's income would benefit the pharmacies, they would have to spend heavily on new equipment and software. The government's proposals on charges are rejected by the Social Democratic (ESSD) opposition and by the Communist Party (KSEM).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze